1Jessup M. and Brozena S. Heart Failure. New England Journal of Medicine. 2003. 348(20):2007–18.
2Schweizerisches Gesundheitsobservatorium. Herzinsuffizienz. 2014 [cited 2018 21.02.]; Available from: https://www.obsan.admin.ch/de/indikatoren/herzinsuffizienz.
3Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.
4Mamas MA, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail. 2017;19(9):1095–104.
5Askoxylakis V, et al. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer. 2010;10:105.
6Maisel AS, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161–7.
7Mair J, et al. Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care? Eur Heart J Acute Cardiovasc Care, 2017;6(4):321–8.
8Braunwald E. Biomarkers in heart failure. N Engl J Med, 2008;358(20):2148–59.
9Maisel A, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10(9):824–39.
10McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med. 2003;4(2):72–80.
11Bayes-Genis A, Barallat J, Richards AM. A Test in Context: Neprilysin: Function, Inhibition, and Biomarker. J Am Coll Cardiol. 2016;68(6):639–53.
12Volpe M, Rubattu S, Burnett J Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J. 2014;35(7):419–25.
13Wieczorek SJ, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J. 2002;144(5):834–9.
14Mant JDJ, Roalfe A, Barton P, Cowie MR. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009;13(32).
15Anwaruddin S, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47(1):91–7.
16Yancy CW, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):137–161.
17Thygesen K, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J. 2012;33(16):2001–6.
18Mueller C, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350(7):647–54.
19Bay M, et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart. 2003;89(2):150–4.
20Battaglia M, et al. Accuracy of B-Type Natriuretic Peptide Tests to Exclude Congestive Heart Failure: Systematic Review of Test Accuracy Studies. Archives of Internal Medicine. 2006;166(10):1073–1080.
21Chow SL, et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2017;135(22):1054–91.
22Iwaz JA, Maisel AS. Recent advances in point-of-care testing for natriuretic peptides: potential impact on heart failure diagnosis and management. Expert Rev Mol Diagn, 2016;16(6):641–50.
23Behnes M, et al. Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema. Int J Cardiol. 2009;135(2):165–74.
24Rutten JH, et al. N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome. Am Heart J. 2008;156(1):71–7.
25Rosemann T. Persönliche Mitteilung.
26Bibbins-Domingo K, et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297(2):169–76.
27Jernberg T, et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and non ST-segment elevation. J Am Coll Cardiol. 2002;40:437–45.
28Bettencourt P, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation, 2004;110(15):2168–74.
29Blankenberg S, et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006;114(3):201–8.
30Kucher N, et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation. 2003;107(12):1576–8.
31Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation. 2003;107(20):2545–7.
32Wolsk E, et al. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. J Am Heart Assoc. 2017;6(6).
33de Lemos JA, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345(14):1014–21.
34Leistner DM, et al. Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study. Clin Res Cardiol. 2013;102(4):259–68.
35Ledwidge M, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310(1):66–74.
36Darkner S, et al. Natriuretic Propeptides as Markers of Atrial Fibrillation Burden and Recurrence (from the AMIO-CAT Trial). Am J Cardiol. 2017;120(8):1309–15.
37Alibay Y, et al. Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea. Biomed Pharmacother. 2005;59(1–2):20–4.
38Lainchbury JG, et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol. 2003;42(4):728–35.
39McCullough PA NM, McCord J. B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure. Analysis From Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106(4):416–22.
40Daniels LB, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J. 2006;151(5):999–1005.
41Zile MR, et al. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016;68(22):2425–36.
42Ibrahim NE, et al. Effect of Neprilysin Inhibition on VariousNatriuretic Peptide Assays. Journal of the American College of Cardiology. 2019;73(11):1273–84.
43Huelsmann M, et al. PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): A Prospective Randomized Controlled Trial. Journal of the American College of Cardiology. 2013;62(15):1365–72.
44Fonseca C. Diagnosis of heart failure in primary care. Heart Failure Reviews. 2006;11(2):95–107.
45Januzzi JL, et al. N-Terminal Pro–B-Type Natriuretic Peptide in the Emergency Department: TheICON-RELOADED Study. Journal of the American College of Cardiology. 2018;71(11):1191–200.
46Kozhuharov N, et al. Prospective validation of N-terminal pro B-type natriuretic peptide cut-off concentrations for the diagnosis of acute heart failure. European Journal of Heart Failure. 2019;0(0).
47Price S, et al. Expert consensus document: Echocardiography and lung ultrasonography for the assessment and management of acute heart failure. Nat Rev Cardiol. 2017;14(7):427–40.
